Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cost-benefit analysis of newer versus older antidepressants - Pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants
Autore:
Laux, G;
Indirizzi:
Bezirkskrankenhaus Gabersee, D-83512 Wasserburg, Germany Bezirkskrankenhaus Gabersee Wasserburg Germany D-83512 sserburg, Germany
Titolo Testata:
PHARMACOPSYCHIATRY
fascicolo: 1, volume: 34, anno: 2001,
pagine: 1 - 5
SICI:
0176-3679(200101)34:1<1:CAONVO>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; HEALTH MAINTENANCE ORGANIZATION; PRIMARY-CARE; MAJOR DEPRESSION; SERTRALINE; FLUOXETINE; PHARMACOTHERAPY; SELECTION; MANAGEMENT; PAROXETINE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Laux, G Bezirkskrankenhaus Gabersee, D-83512 Wasserburg, Germany Bezirkskrankenhaus Gabersee Wasserburg Germany D-83512 , Germany
Citazione:
G. Laux, "Cost-benefit analysis of newer versus older antidepressants - Pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants", PHARMACOPS, 34(1), 2001, pp. 1-5

Abstract

Changes in the social and health services over the last years have forced doctors to concern themselves with cost benefit calculations and budget forecasting. Cost considerations are a (co-) determinant in the choice of antidepressants as well as neuroleptics and/or antipsychotics. In recent years,pharmacoeconomic studies have been performed to answer the question as to what extent treatment with new antidepressants, in particular SSRls, is actually less expensive than treatment with (generic) tricyclic antidepressants due to better safety profiles and higher compliance in spite of the considerably higher retail price. Following descriptions of the methodological principles, the currently available studies are presented and discussed critically in this report. It can be stated that the economic value of different antidepressants can not be decided definitively at the present time. The available data do not allow the conclusion that SSRls should be preferred over tricyclic antidepressants with the argument that the treatment as a whole is more cost effective in spite of the higher costs. Changes in policy on social and health services over the last few years have forced office-based physicians (and increasingly also clinic-based physicians) to concern themselves more with cost benefit calculations and budgetestimates. Thus, cost aspects have also become a decisive factor in drug selection. In the last few years "sociopharmacoeconomic" evaluations have been carried out to establish a data base to answer the question of whether the total cost of treatment with newer antidepressant drugs (especially SSRls) is the same or lower than that of treatment with (generic) tricyclic preparations [3]. In particular, these studies have been conducted in view of potential advantages of newer antidepressants in terms of safety and patients compliance. Resulting from the introduction of new antidepressant drugs, the costs of a day's treatment now vary widely (the most expensive being roughly five times as high as the lowest - see Fig. 1).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:27:31